Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading ...

Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurogene (NGNE – Research Report), with a price ...

The company also said it does not expect to move forward with the NGN-101 CLN5 Batten disease gene therapy program. Price Action: NGNE stock is down 44% at $40.05 at last check Tuesday.

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

A Neurogene gene therapy in development for the rare neurodevelopmental disorder Rett syndrome has encouraging early data in a small group of patients, an interim readout that comes a week after a ...

Stifel raised the firm’s price target on Neurogene (NGNE) to $60 from $44 and keeps a Buy rating on the shares. The firm believes preliminary NGN-401 Phase 1/2 data “transcend the signal-to ...

Neurogene (NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a phase 1/2 trial for NGN-401, its gene therapy candidate targeting Rett ...